Open Interest and Volume Dynamics
On 20 Apr 2026, Alkem Laboratories recorded an open interest (OI) of 14,213 contracts in its derivatives, marking a 10.57% increase from the previous OI of 12,854. This rise of 1,359 contracts is significant in the context of the stock’s recent trading activity and suggests a growing conviction among traders. The volume for the day stood at 10,456 contracts, indicating robust participation alongside the OI increase.
The futures value associated with Alkem’s derivatives reached ₹9,041.66 lakhs, while the options segment exhibited an exceptionally high notional value of approximately ₹6,597.78 crores. The combined total derivatives value was ₹10,053.68 lakhs, underscoring the stock’s liquidity and attractiveness in the derivatives market.
Underlying the derivatives activity, Alkem’s spot price closed at ₹5,670, just 4.67% shy of its 52-week high of ₹5,933.5. This proximity to the peak price level, coupled with the rising OI, suggests that market participants are positioning for a potential upward move or sustained strength in the near term.
Price Performance and Moving Averages
Alkem Laboratories has outperformed its Pharmaceuticals & Biotechnology sector by 1.72% on the day, registering a 1.49% gain compared to the sector’s marginal decline of 0.11% and the Sensex’s fall of 0.25%. The stock has been on a two-day consecutive gain streak, delivering a cumulative return of 1.78% over this period.
Technically, the stock is trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling a strong bullish trend. This technical strength is likely contributing to the increased open interest as traders and investors gain confidence in the stock’s momentum.
Investor Participation and Liquidity
Investor participation has also been on the rise, with delivery volume on 17 Apr reaching 85,180 shares, a 9.39% increase over the five-day average delivery volume. This indicates that not only are traders active in the derivatives market, but long-term investors are also accumulating shares, reinforcing the bullish sentiment.
Liquidity remains ample, with the stock’s traded value supporting a trade size of approximately ₹1.52 crore based on 2% of the five-day average traded value. This liquidity facilitates smooth execution of large trades and supports the growing derivatives activity.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Market Positioning and Directional Bets
The surge in open interest alongside rising prices and volume suggests that market participants are increasingly bullish on Alkem Laboratories. The 10.57% increase in OI is indicative of fresh positions being established rather than existing ones being squared off, which often signals directional conviction.
Given the stock’s strong technical setup and improving fundamentals, traders may be betting on further upside potential. The fact that the stock is trading above all major moving averages supports this view, as it reflects sustained buying interest and positive momentum.
Moreover, the stock’s Mojo Score has improved to 62.0, with a Mojo Grade upgrade from Sell to Hold on 10 Apr 2026. This upgrade reflects a more favourable outlook based on a comprehensive assessment of financial metrics, trend quality, and market positioning. While the grade remains a Hold, the positive revision signals that the stock is stabilising and could be poised for further gains.
Valuation and Market Capitalisation
Alkem Laboratories is classified as a mid-cap company with a market capitalisation of ₹67,088 crore. This sizeable valuation places it among the prominent players in the Pharmaceuticals & Biotechnology sector, which has been underpinned by steady demand and innovation-driven growth.
The stock’s valuation metrics and liquidity profile make it an attractive candidate for both institutional and retail investors seeking exposure to the pharmaceutical space. The recent derivatives activity further enhances its appeal by offering multiple avenues for strategic positioning.
Sector and Benchmark Comparison
Compared to the broader Pharmaceuticals & Biotechnology sector, Alkem Laboratories has demonstrated relative strength. While the sector declined by 0.11% on the day, Alkem gained 1.49%, underscoring its outperformance. The Sensex’s decline of 0.25% further highlights the stock’s resilience amid broader market weakness.
This relative outperformance is a key factor driving increased open interest, as traders seek to capitalise on the stock’s momentum and sector leadership.
Holding Alkem Laboratories Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Outlook and Investor Considerations
Investors and traders should note that while the open interest surge and price momentum are encouraging, the stock’s current Mojo Grade of Hold suggests a cautious approach. The upgrade from Sell to Hold indicates improving fundamentals but also highlights the need for further confirmation before a strong buy recommendation can be made.
Market participants should monitor upcoming quarterly results, sector developments, and broader market trends to gauge sustainability of the current momentum. The stock’s liquidity and active derivatives market provide ample opportunities for tactical positioning, whether through futures, options, or spot trades.
Given the stock’s proximity to its 52-week high and the rising investor participation, a breakout above the ₹5,933.5 level could trigger further buying interest and potentially elevate the stock to a Strong Buy status in the near future.
Summary
Alkem Laboratories Ltd’s recent surge in open interest by over 10% alongside strong volume and price gains reflects heightened market interest and bullish positioning. The stock’s technical strength, improved Mojo Grade, and relative outperformance within its sector underpin a positive near-term outlook. However, investors should balance optimism with prudence, considering the Hold rating and the need for confirmation of sustained momentum.
Overall, the derivatives market activity signals that Alkem is firmly on the radar of traders and investors alike, making it a key stock to watch in the Pharmaceuticals & Biotechnology space.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
